Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in Kuwait, Oman, Qatar, Bahrain, and the United Arab Emirates (UAE).
Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m).
Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP).
Citius Pharmaceuticals’ subsidiary Citius Oncology has signed an exclusive distribution agreement with Uniphar to enable access to Lymphir (denileukin diftitox-cxdl) in selected European countries.
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas.
Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn.
AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.
Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and potential commercialisation of its botensilimab and balstilimab (BOT/BAL) immunotherapy combination programme.
BD (Becton, Dickinson and Company) has announced a $110m investment to expand its production of prefillable syringes in the US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.